Investors bought shares of Celgene Corp. (NASDAQ:CELG) on weakness during trading hours on Thursday. $112.27 million flowed into the stock on the tick-up and $90.44 million flowed out of the stock on the tick-down, for a money net flow of $21.83 million into the stock. Of all stocks tracked, Celgene Corp. had the 12th highest net in-flow for the day. Celgene Corp. traded down ($0.34) for the day and closed at $101.42

Several research analysts recently commented on CELG shares. Jefferies Group reaffirmed a “buy” rating and issued a $138.00 target price on shares of Celgene Corp. in a research note on Sunday, July 10th. Vetr downgraded shares of Celgene Corp. from a “buy” rating to a “hold” rating and set a $106.06 target price on the stock. in a research note on Wednesday, July 6th. JMP Securities reaffirmed a “buy” rating and issued a $152.00 target price on shares of Celgene Corp. in a research note on Wednesday, July 6th. Credit Suisse Group AG reaffirmed an “outperform” rating and issued a $140.00 target price on shares of Celgene Corp. in a research note on Tuesday. Finally, Morgan Stanley reaffirmed a “hold” rating on shares of Celgene Corp. in a research note on Thursday, June 30th. Five investment analysts have rated the stock with a hold rating and twenty-four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $140.54.

The company’s 50 day moving average is $102.32 and its 200-day moving average is $103.67. The firm has a market capitalization of $78.56 billion and a PE ratio of 49.33.

Celgene Corp. (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported $1.32 EPS for the quarter, beating the Zacks’ consensus estimate of $1.29 by $0.03. The business earned $2.51 billion during the quarter, compared to analysts’ expectations of $2.59 billion. The firm’s quarterly revenue was up 20.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.07 earnings per share. On average, equities research analysts expect that Celgene Corp. will post $5.68 earnings per share for the current fiscal year.

In other news, insider Robert J. Hugin sold 75,000 shares of the business’s stock in a transaction that occurred on Monday, June 20th. The stock was sold at an average price of $100.16, for a total value of $7,512,000.00. Following the completion of the sale, the insider now directly owns 1,122,201 shares in the company, valued at $112,399,652.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Other hedge funds have bought and sold shares of the company. Vanguard Group Inc. boosted its stake in Celgene Corp. by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 46,398,324 shares of the biopharmaceutical company’s stock worth $5,556,664,000 after buying an additional 808,611 shares during the period. Jennison Associates LLC boosted its stake in Celgene Corp. by 14.1% in the fourth quarter. Jennison Associates LLC now owns 14,106,160 shares of the biopharmaceutical company’s stock worth $1,689,354,000 after buying an additional 1,741,019 shares during the period. Edgewood Management LLC boosted its stake in Celgene Corp. by 5.1% in the fourth quarter. Edgewood Management LLC now owns 7,665,713 shares of the biopharmaceutical company’s stock worth $918,046,000 after buying an additional 373,288 shares during the period. Morgan Stanley boosted its stake in Celgene Corp. by 7.9% in the fourth quarter. Morgan Stanley now owns 3,883,304 shares of the biopharmaceutical company’s stock worth $465,065,000 after buying an additional 284,929 shares during the period. Finally, BB Biotech AG boosted its stake in Celgene Corp. by 0.6% in the fourth quarter. BB Biotech AG now owns 3,609,298 shares of the biopharmaceutical company’s stock worth $432,250,000 after buying an additional 20,000 shares during the period.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.